Sandoz reports third-quarter and nine-month 2024 salesAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz reports second-quarter sales and half-year 2024 resultsAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz reports first quarter 2024 salesAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz reports fourth quarter 2023 sales and full-year 2023 resultsAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz announces changes in the Board of DirectorsAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient careBasel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today.
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in GermanyBasel, November 10, 2023 – Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.
Sandoz successfully issues EUR 2.0 billion inaugural EurobondsNOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
Sandoz successfully issues CHF 750 million in inaugural bondsBasel, October 26, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of CHF 750 million.
Sandoz reports year-to-date sales for the first nine months of 2023Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicinesBasel, October 4, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company.
